$NEOG

UBS upgraded SolarEdge (SEDG) to Buy with a $42 target, citing FCC benefits. Wolfe upgraded DT Midstream (DTM) to Outperform with a $145 target. Piper upgraded Neogen (NEOG) to Overweight with a $14 target. UBS upgraded Argenx (ARGX) to Buy with a $1,400 target. National Bank upgraded Scotiabank (BNS) to Outperform with a C$142 target. JPMorgan and BofA downgraded Intuit (INTU) to Neutral with a $331 target. Truist downgraded Dick's Sporting (DKS) and Nike (NKE). Wells downgraded GoDaddy (GDDY).

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond

Neogen Corporation (NEOG) stock rose 3.0% in pre-market trading after Piper Sandler upgraded it to Overweight and raised its price target to $14. The firm cited improved operating performance, accelerating growth in the Food Safety segment, and effective execution of a turnaround strategy. Neogen's recent earnings beat and raised guidance also contributed to the positive sentiment.

A Michigan federal judge dismissed an investor lawsuit against food safety company Neogen, which alleged Neogen hid postmerger financial problems tied to its combination with a division of 3M, according to the court. The ruling removes the claims related to alleged 3M integration and related disclosures.

Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On August 3, 2026, Mr. Thierry Bernard resigned from the Board of Directors of Neogen Corporation. SIGNATURES Pursuant t

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

Neogen (NASDAQ: NEOG) reported Q2 CY2026 results. Revenue was $225.3 million, flat year over year but 6% above estimates. Full-year revenue guidance midpoint was $882.5 million, 3.9% above analysts’ forecasts. Non-GAAP EPS was $0.09, 58.8% above consensus. The stock rose 7.1% to $10.07 after results.

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neogen Reports Fourth Quarter and Full Fiscal Year 2026 Financial Results Delivered Strong Core Growth in Q4 FY26 with Food Safety Core Growth Highest Since FY23 • Fiscal fourth quarter 2026 revenue of $225.3 million representing growth of (0.1%) and Core Growth 1 of